Multivalent-based drug design applied to serotonin 5-HT(4) receptor oligomers.
Historically treated as monomeric polypeptides, G protein-coupled receptors (GPCRs) have been shown to exist and function as constitutively formed dimers or oligomers. The quaternary structure of GPCRs may modulate ligand binding properties through allosteric mechanisms offering new opportunities for drug design by exploiting multivalency. In this context, multivalent ligands versus bivalent-ligands, possessing two binding motifs connected by a linker, have been investigated and have revealed striking differences in their functional properties compared to their monovalent counterparts. These bi-functional drugs, which are able to activate the two protomers in a dimer simultaneously, emerge as novel and promising drugs for a variety of multi-factorial diseases. In this review, key requirements for the successful design and synthesis of GPCR multivalent ligands composed of pharmacophores and a linker will be discussed. We will then focus on the 5-HT(4) receptor (5-HT(4)R), whose ligands emerged as promising drugs for a variety of central nervous disorders. Upon description of biochemical and biophysical evidences of 5-HT(4)R dimerization, we will present the multivalent ligand approach, which was assisted by molecular docking experiments on the 5-HT(4)R dimer model.
Lezoualc'h
Frank
F
Inserm, U769, Châtenay-Malabry, France.
Jockers
Ralf
R
Berque-Bestel
Isabelle
I
D000818:Animals; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000503:physiopathology; D019281:Dimerization; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D008024:Ligands; D011485:Protein Binding; D043562:Receptors, G-Protein-Coupled; D044422:Receptors, Serotonin, 5-HT4 / Q000187:drug effects* / Q000378:metabolism
D008024:Ligands; D043562:Receptors, G-Protein-Coupled; D044422:Receptors, Serotonin, 5-HT4